

Measured GFR as “Gold Standard”—All that Glitters Is Not Gold?

Chi-yuan Hsu and Nisha Bansal

Clin J Am Soc Nephrol 6: 1813–1814, 2011. doi: 10.2215/CJN.06040611

Glomerular filtration rate (GFR) is the parameter that has been used most commonly as the “overall index” of renal function. Historically, inulin has been considered the ideal filtration marker used to determine GFR. The classic procedure for measuring inulin clearance is rigorous and includes a continuous intravenous infusion, multiple repeat blood and urine collections, and careful timing of blood sampling.

Because such direct measurement of GFR is cumbersome and invasive, it is not practical for day-to-day clinical practice. As a result, numerous equations to estimate GFR have been developed. The oldest equation is the Cockcroft–Gault equation (3), which actually estimates creatinine clearance rather than GFR. In 1999, the first description of what became known as the six-variable Modification of Diet in Renal Disease (MDRD) study equation was published (4). This was followed by the “abbreviated” four-variable MDRD equation, which revolutionized the field (5). It was widely adopted in research studies and changed clinical practice by becoming the foundation for the widespread automatic reporting of estimated GFR (eGFR) whenever serum creatinine measurements are ordered (6). The next major advance in the application of GFR estimating equations was standardized calibration of serum creatinine measurements across laboratories (7). Even after calibration, the MDRD equation has been observed to give lower readings compared with directly measured GFR at higher GFR levels (8–10). To overcome this limitation and to base the GFR estimating equation on a more diverse population, the same research group recently developed the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (11).

The study by Murata *et al.* (12) in this issue of *CJASN* compared the accuracy of the MDRD and the CKD-EPI equations for estimating GFR in a large, diverse population with and without chronic kidney disease (CKD). The study included 5238 patients who underwent simultaneous outpatient serum creatinine and renal iothalamate clearance measurements. Clinical indications for the measurements included potential kidney donor, postnephrectomy kidney donors, native CKD, kidney transplant recipients, and non-kidney transplant recipients. The authors concluded that, overall, the MDRD equation was less biased for those with native CKD, kidney transplant recipients

and other organ recipients. The CKD-EPI equation was less biased overall for potential kidney donors and postnephrectomy donors.

There have been many past—and there likely will be many future—studies evaluating the performance of eGFR compared with directly measured GFR. The assumption behind all of these studies is that it is clinically important for the eGFR to match the measured GFR. The assumption that the measured GFR is the “gold standard” is so commonly made that it is not explicitly acknowledged, but perhaps this should be reconsidered for several reasons.

First is that there are numerous ways to measure GFR directly, and these different methods often yield measurements that do not agree with each other. For example, examination of the Bland–Altman plot of an oft-cited study of nonradioactive iothexol (plasma) *versus* inulin (urinary) clearance suggested that the two readings often disagreed by as much as 20% (13). Another study showed that among patients with preserved GFR, iothalamate-measured GFR was approximately 20 ml/min per 1.73 m² higher than inulin-measured GFR (127.1 ± 12.4 *versus* 108.3 ± 14.1 ml/min per 1.73 m²) (14). In the literature, any direct measure of GFR is typically taken to be the gold standard, without much attention paid to the details of the methodology. For example, in the study by Murata *et al.* (12), measured GFR was determined by using a single-period urine and plasma measurement, which may limit the accuracy of the measurement. In contrast, research studies have often used multiple-period measures to reduce the impact of errors in timing of blood and urine sampling.

Second, even if the same method is used, direct measures of GFR may not agree with each other when repeated. For example, one analysis of the MDRD and African American Study of Kidney Disease and Hypertension (AASK) studies found that measured GFR, as determined by the urinary clearance of ¹²⁵I iothalamate, had substantial variability across visits within the same individual. When repeated on average 62 days apart, 8.0% of the second measured GFR gave results >30% different from the first measured GFR (15). Data such as these make untenable the belief that any single measurement of GFR represents “the true” renal function.

Third, measured GFR has not been shown to be

Division of Nephrology,
University of California,
San Francisco, San
Francisco, California

Correspondence: Dr.
Chi-yuan Hsu, Division
of Nephrology,
University of California,
San Francisco, 513
Parnassus Avenue, 672
HSE, Box 0532, San
Francisco, CA 94143-
0532. Phone: 415-353-
2379; Fax: 415-476-
3381; E-mail: hsuchi@
medicine.ucsf.edu

better than other markers of kidney disease at predicting outcomes associated with poor kidney function. In a study comparing the strengths of association among four measures of renal function (1/serum creatinine, 1/serum cystatin C, MDRD equation eGFR, and iothalamate measured GFR) and four outcomes (all-cause mortality, cardiovascular disease mortality, kidney failure, and a composite outcome of kidney failure and all-cause mortality), measured GFR was not the strongest predictor in any of the four outcomes. For cardiovascular disease mortality, the adjusted hazard ratio (per 1-SD decrease) for measured GFR was 1.28 (95% confidence interval [CI] 1.04 to 1.59) but 1.64 (95% CI 1.28 to 2.08) for 1/cystatin C. In adjusted models for kidney failure, the hazard ratio for measured GFR was 2.41 (95% CI 2.15 to 2.70) compared with 2.81 (95% CI 2.48 to 3.18) for 1/creatinine (16). In addition, a recent cross-sectional study showed that measured GFR was not consistently superior to either creatinine-based or cystatin C–based eGFR in explaining comorbidities related to renal disease (e.g., anemia, hyperkalemia, metabolic acidosis, and hyperphosphatemia) (17).

The exact reasons for the disappointing performance of measured GFR are not known but may be related to the fact that direct measures of GFR quantify renal function over a relatively short period, typically only several hours. Known variations in GFR are associated with time of day, posture, and diet (17–21). Estimates of renal function using endogenous filtration markers such as creatinine may provide a better measure of average renal function over a period of days to weeks, which is conceptually the underlying physiologic parameter of interest (22). Furthermore, measured GFR is subject to unique sources of measurement errors related to the timing of collection of urine and blood samples (17).

To conclude, investigations regarding estimating and measuring GFR have recently occupied much time and attention of many in academic nephrology. We believe that it is time for a general reassessment of these efforts. The principal clinical purpose of assessing a patient's renal function is to anticipate complications, enabling better screening and treatment decisions. Determining with great accuracy a certain physiologic parameter—actual GFR—is a less important goal.

Disclosures

None.

References

- Berger EY, Farber SJ, Earle DP, Jackenthal R: Comparison of the constant infusion and urine collection techniques for the measurement of renal function. *J Clin Invest* 27: 710–716, 1948
- Smith H: *The Kidney: Structure and Function in Health and Disease*, New York, Oxford University Press, 1951
- Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. *Nephron* 16: 31–41, 1976
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 130: 461–470, 1999
- Levey AS, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine. *J Am Soc Nephrol* 11: 155A, 2000 [abstract]
- National Kidney Disease Education Program: Laboratory professionals. Available at: nkddep.nih.gov/resources/laboratory_reporting.htm. Accessed June 21, 2011
- Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. *Ann Intern Med* 145: 247–254, 2006
- Poggio ED, Wang X, Greene T, Van Lente F, Hall PM: Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. *J Am Soc Nephrol* 16: 459–466, 2005
- Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS: Evaluation of the Modification of Diet in Renal Disease study equation in a large diverse population. *J Am Soc Nephrol* 18: 2749–2757, 2007
- Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG: Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. *Ann Intern Med* 141: 929–937, 2004
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150: 604–612, 2009
- Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, Lieske JC: Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. *Clin J Am Soc Nephrol* 6: 1963–1972, 2011.
- Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iothexol as a measure of glomerular filtration rate. *J Am Soc Nephrol* 6: 257–263, 1995
- Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG: Utility of radioisotopic filtration markers in chronic renal insufficiency: Simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. *Am J Kidney Dis* 16: 224–235, 1990
- Kwong YT, Stevens LA, Selvin E, et al: Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. *Am J Kidney Dis* 56: 39–49, 2010
- Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ: Cystatin C as a risk factor for outcomes in chronic kidney disease. *Ann Intern Med* 147: 19–27, 2007
- Hsu CY, Probert K, Hamm L, He J, Miller E, Ojo A, Shlipak M, Teal V, Townsend R, Weir M, Wilson J, Xie D, Feldman H: Is iGFR really better than eGFR? *J Am Soc Nephrol* 2009; 20: 1A [abstract]
- Koopman MG, Koomen GC, Krediet RT, de Moor EA, Hoek FJ, Arisz L: Circadian rhythm of glomerular filtration rate in normal individuals. *Clin Sci (Lond)* 77: 105–111, 1989
- Hansen HP, Hovind P, Jensen BR, Parving HH: Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy. *Kidney Int* 61: 163–168, 2002
- Wan LL, Yano S, Hiromura K, Tsukada Y, Tomono S, Kawazu S: Effects of posture on creatinine clearance and urinary protein excretion in patients with various renal diseases. *Clin Nephrol* 43: 312–317, 1995
- Hostetter TH: Human renal response to meat meal. *Am J Physiol* 250: F613–F618, 1986
- Hsu CY, Chertow GM, Curhan GC: Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. *Kidney Int* 61: 1567–1576, 2002

See related article, “Relative Performance of the MDRD and CKD-EPI Equations for Estimating Glomerular Filtration Rate among Patients with Varied Clinical Presentations,” on pages 1963–1972.